Charles River Labs Reports Mixed Q1 Results, Reaffirms 2026 Guidance, and Repurchases $200M in Stock
Summary
Charles River Labs reported a Q1 GAAP net loss due to divestiture, but reaffirmed 2026 guidance and executed a significant $200 million share repurchase, signaling strategic execution and capital return despite mixed operational results.
Key Events
-
Mixed First Quarter 2026 Financial Results
Reported Q1 2026 revenue of $995.8 million, a 1.2% increase year-over-year, but organic revenue declined by 1.5%. The company posted a GAAP net loss of $(14.8) million, or $(0.30) per diluted share, primarily due to a $118.0 million loss on assets held for sale related to divestitures. Non-GAAP diluted earnings per share decreased by 12.0% to $2.06.
-
2026 Guidance Reaffirmed
The company reaffirmed its 2026 organic revenue growth and non-GAAP earnings per share guidance, which remains in the range of $10.80 – $11.30. GAAP EPS guidance was updated to $5.35 – $5.85, reflecting the impact of divestitures.
-
Strategic Divestitures Completed
Completed the previously announced divestiture of the CDMO and Cell Solutions businesses on May 6, 2026, and expects to complete the sale of certain European Discovery Services sites in May 2026, aligning with its strategy to refocus on core competencies.
-
Significant Share Repurchase Program Update
Repurchased 1.1 million shares for a total of $200.0 million during the first quarter of 2026. This leaves $800.0 million remaining under the $1.0 billion stock repurchase authorization approved in October 2025.
Analysis
Charles River Laboratories reported mixed first-quarter results, with a GAAP net loss primarily driven by a significant loss on the divestiture of its CDMO and Cell Solutions businesses. While organic revenue declined and non-GAAP earnings per share decreased, the company reaffirmed its full-year 2026 organic revenue and non-GAAP EPS guidance, signaling stability in its outlook. The completion of strategic divestitures aims to refocus the company on core competencies. Furthermore, a substantial $200 million share repurchase in the quarter demonstrates a commitment to returning capital to shareholders and reflects management's confidence, which is a strong positive signal for investors.
At the time of this filing, CRL was trading at $181.75 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $9B. The 52-week trading range was $113.89 to $228.88. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.